Bionical Solutions, a leading provider of technology enabled engagement and healthcare services … Continue reading “Bionical Solutions shortlisted as a finalist for the HSJ Partnership Awards 2021”
Brings substantial pharmaceutical expertise to lead the development and commercialization of olorofim … Continue reading “Francesco Maria Lavino appointed Chief Executive Officer of F2G Ltd”
Artios to receive $20 million up-front payment in addition to near term … Continue reading “Arix Bioscience portofolio company Artios announces collaboration with Novartis to create next generation DDR cancer therapies”
Novartis to leverage Artios’ discovery platform to identify DDR targets for use with Novartis’ … Continue reading “Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies”
Neuraxpharm, Europe’s leading CNS specialty company, announces expansion into the Nordics Establishes … Continue reading “Neuraxpharm strengthens European presence with expansion into the Nordics”
rix announces a new portfolio company, Pyxis Oncology, with a 5.6% ownership … Continue reading “Arix leads $152 million Series B financing for Pyxis Oncology”
An app that puts critical user information in the hands of healthcare … Continue reading “Biocomposites Launches Biocomposites Companion”
Today, the Novo Holdings REPAIR Impact Fund announced the opening of its … Continue reading “Novo Holdings REPAIR Impact Fund Announces Second Global Call for New Investment Proposals to Fight AMR”
Primary endpoint achieved with >99% nasal bacterial load reduction (p<0.0001) Excellent safety … Continue reading “Destiny Pharma Reports Positive Phase 2b Results for XF-73 Nasal Gel”
Destiny Pharma to Join Equity Development Webinar on Positive Phase 2b Top-line … Continue reading “Destiny Pharma to Join Equity Development Webinar”
Niel (Belgium) eTheRNA immunotherapies NV (‘eTheRNA’), a clinical-stage company developing mRNA-based immunotherapies as … Continue reading “Consortium led by eTheRNA immunotherapies Awarded EU Commission TIGER Grant of EUR 6.9 million”
Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing … Continue reading “Futura Medical Receives US FDA Agreement for Confirmatory Clinical study, FM71 for MED3000”
Depixus®, a biotechnology company developing a unique platform technology for the fast, … Continue reading “Depixus® announces peer-reviewed publication describing the detection of sequence variation and base modifications on DNA and RNA using its novel MAGNA technology”
Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing … Continue reading “Futura Medical Receives Recommendation for Approval of MED3000 from EU Notified Body”
Novo Holdings’ 2020 result is based on a strong performance from both … Continue reading “Novo Holdings posts record income and returns of DKK 29 billion (EUR 4 billion) in 2020”
ExeVir, which is developing single domain antibody therapies providing broad protection against … Continue reading “ExeVir Announces Close of $50 million/ EUR42 million Series A Financing”
Deep Branch announces EUR 8m Series A round led by Novo Holdings … Continue reading “Deep Branch Announces €8M Series A Round led by Novo Holdings and DSM Venturing”
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced the … Continue reading “Calliditas Announces Submission of New Drug Application to U.S. FDA for Nefecon in Patients with Primary IgA Nephropathy”
NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the close … Continue reading “NeoPhore Announces £15.2m Financing to Advance DNA Mismatch Repair Pipeline”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2021 Optimum Strategic Communications All rights reserved.
8 Devonshire Square
Spitalfields
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com
